Does Dr. LAURA BAGDONAITE BEJARANO have financial conflicts of interest?

Dr. LAURA BAGDONAITE BEJARANO (M.D.) has received a total of $63 in pharmaceutical and medical device industry funding between 2021 and 2025. This includes $63 in personal promotional payouts (consulting, meals, travel) and $0 in clinical research grants. Financial ties do not automatically imply conflict of interest, but are disclosed under the Sunshine Act.

Which pharmaceutical companies pay Dr. LAURA BAGDONAITE BEJARANO?

According to CMS Open Payments data, Dr. LAURA BAGDONAITE BEJARANO received funding from ABBVIE ($29), BIOTISSUE HOLDINGS ($20), and EYEVANCE PHARMACEUTICALS ($14).

Does Dr. LAURA BAGDONAITE BEJARANO receive research grants or speaking fees?

Dr. LAURA BAGDONAITE BEJARANO has received $63 in general promotional payments (such as consulting honoraria, meals, and speaking fees) and $0 in clinical research grants.

DR. LAURA BAGDONAITE BEJARANO

M.D.Real-Time Hydrated

Specialty: Ophthalmology, Pediatric Ophthalmology and Strabismus Specialist

Practice Location: VIRGINIA BEACH, VA 23452

NPI Number: 1659720589

LIFETIME INDUSTRY VALUE

$63

2021 – 2025 Cumulative

Conflict of Interest Analysis

Dr. BAGDONAITE BEJARANO is a verified Ophthalmology, Pediatric Ophthalmology and Strabismus Specialist practitioner based in VIRGINIA BEACH, VA.

Between 2021 and 2025, Dr. BAGDONAITE BEJARANO had an overall industry promotional and research financial footprint of $63 as recorded in the federal CMS Open Payments database.

$63 was received in general payments, which include consultation fees, travel expenses, honoraria, and sponsored meals.
$0 was allocated to sponsored clinical trials and medical research activities.

Dr. BAGDONAITE BEJARANO's primary funding source is ABBVIE, which accounts for $29 (representing 46.1% of overall industry footprint).

Data coverage: 2021 – 2025 · Source: CMS Open Payments · CMS publishes each year's data around June 30 of the following year.

Payout Trend Over Time

General Payments

Research Funding

Top Funding Entities

Pharmaceutical & Device Manufacturers making direct payments

ABBVIE

Rank 1

$29

46.1%

BIOTISSUE HOLDINGS

Rank 2

$20

31.9%

EYEVANCE PHARMACEUTICALS

Rank 3

$14

22%

Itemized Transaction Archives

Direct live query to Socrata CMS Open Payments API (Bypasses local DB)

Year:

2025

Filter < $250

Click "Load Live Logs" to query the federal Open Payments registry directly.

Frequently Asked Questions

Answers compiled using federal transparency disclosure records under the Sunshine Act.